Dual Action of Dipyridamole in Experimental Rheumatoid Arthritis: Suppression of Joint Inflammation and Upregulation of Muscle Anabolism via Adenosine and AMPK Pathways - Report - MDSpire

Biphasic Effects of Dipyridamole in Experimental Models of Rheumatoid Arthritis: Inhibition of Joint Inflammation and Enhancement of Muscle Anabolism through Adenosine and AMPK Signaling Pathways

  • By

  • Miguel Marco-Bonilla

  • Maria Fresnadillo

  • Irene Sanchez-Platero

  • Macarena de la Riva-Bueno

  • Fernando Huete-Toral

  • Gonzalo Carracedo

  • Carmen Conde

  • Yolanda Benitez

  • Pablo Minguez

  • Sandra Carolina Cifuentes

  • Joaquin Rams

  • Gabriel Herrero-Beaumont

  • Raquel Largo

  • Aránzazu Mediero

  • July 1, 2026

Share

Biphasic Effects of Dipyridamole in Experimental Models of Rheumatoid Arthritis

Overview

This study investigates the effects of dipyridamole on joint inflammation and muscle anabolism in rheumatoid arthritis (RA) models.

Background

Rheumatoid arthritis (RA) is a chronic autoimmune disease that leads to joint inflammation and can result in muscle atrophy, known as rheumatoid sarcopenia. The prevalence of rheumatoid sarcopenia ranges from 20% to 44%, highlighting the need for effective treatments that address both inflammation and muscle health. Current therapies, including methotrexate, do not adequately improve muscle condition, necessitating alternative approaches.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

  • Dipyridamole inhibits joint inflammation in experimental models of RA.
  • The drug enhances muscle anabolism through activation of adenosine receptors A2AR and A2BR.
  • Dipyridamole increases extracellular adenosine concentrations by blocking nucleoside transport.
  • Activation of AMPK is facilitated by dipyridamole, contributing to muscle health.

Clinical Implications

Further exploration of adenosine signaling pathways could lead to novel therapeutic strategies for managing rheumatoid sarcopenia.

Conclusion

Dipyridamole shows promise in modulating inflammation and muscle pathology in RA, warranting further investigation into its therapeutic potential.

Related Resources & Content

  1. Frontiers in Immunology, 2026 -- Efficacy and safety of upadacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
  2. Frontiers in Immunology, 2026 -- Cardiovascular safety and early myocardial deformation signal after upadacitinib initiation in immune-mediated inflammatory disorders
  3. Clinical Rheumatology -- The Role of Osteoimmunology in Rheumatoid and Psoriatic Arthritis: Investigating Tofacitinib's Impact on Bone Health
  4. Drug Safety -- Evaluating the Benefit-Risk Profile of Upadacitinib in Patients with Rheumatoid Arthritis: Insights from a Phase III Study Series
  5. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update - PubMed
  6. The Role and Mechanistic Effects of Methotrexate in the Treatment of Rheumatoid Arthritis | European Journal of Rheumatology
  7. Prevalence of sarcopenia in patients with rheumatoid arthritis: a cross-sectional study
  8. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update - PubMed
  9. The Role and Mechanistic Effects of Methotrexate in the Treatment of Rheumatoid Arthritis | European Journal of Rheumatology
  10. Prevalence of sarcopenia in patients with rheumatoid arthritis: a cross-sectional study

Original Source(s)

Dual Action of Dipyridamole in Experimental Rheumatoid Arthritis: Suppression of Joint Inflammation and Upregulation of Muscle Anabolism via Adenosine and AMPK Pathways

  • by Miguel Marco-Bonilla, Maria Fresnadillo, Irene Sanchez-Platero, Macarena de la Riva-Bueno, Fernando Huete-Toral, Gonzalo Carracedo, Carmen Conde, Yolanda Benitez, Pablo Minguez, Sandra Carolina Cifuentes, Joaquin Rams, Gabriel Herrero-Beaumont, Raquel Largo, Aránzazu Mediero

  • July 1, 2026

Related Content

Handgrip weakness is associated with motor cortex atrophy in rheumatoid arthritis: a cross-sectional study with a hand exercise intervention

Radon balneotherapy in rheumatologic diseases: potential mechanisms and implications for cardiovascular autonomic control and inflammation

RA Prescribing Patterns Shift Over 15 Years

An aging Japanese cohort with rheumatoid arthritis saw increasing use of targeted synthetic therapies as glucocorticoid use declined.